Motzer, R.J., Hutson, T.E., Tomczak, P., et al. (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. New England Journal of Medicine, 356, 115-124. doi:10.1056/NEJMoa065044

has been cited by the following article:

• TITLE: Sustained long-term clinical and radiological response with sunitinib for metastatic renal-cell carcinoma (RCC)

  AUTHORS: K. I. Quintyne, T. Neenan, F. Wallis, R. K. Gupta

  KEYWORDS: Renal Cell Carcinoma; Biological Therapy; Sunitinib; Long Term Use

  JOURNAL NAME: Case Reports in Clinical Medicine, Vol.2 No.1, March 22, 2013

  ABSTRACT: The authors herein report the case of a 67-year-old woman with metastatic renal-cell carcinoma (RCC), who has had a sustained clinical and stable radiological response to long-term therapy with an oral multi-targeted tyrosine kinase inhibitor (TKI), sunitinib with minimal lasting toxicity.